Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Page
of 7